Drugs / APR-548
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04638309 | Sep 2021 → Apr 2022 | myelodysplastic syndrome | Aprea Therapeutics | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-10-07 | Aprea Therapeutics | Regulatory Aprea Therapeutics Receives OK from FDA to Initiate Phase 1 Clinical Studies for Next-Generation Mutant p53 Reactivator, APR-548 aprea.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-10-07 | Aprea Therapeutics | Aprea Therapeutics Receives OK from FDA to Initiate Phase 1 Clinical Studies for Next-Generation Mutant p53 Reactivator, APR-548 aprea.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APR-548 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04638309 ↗ |
| Route | Oral | “orally (p.o.) administered APR-548” NCT04638309 ↗ |